Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

ROSWELL, Ga., October 30, 2024--SiteOne Landscape Supply, Inc. (the "Company" or "SiteOne") (NYSE: SITE) announced earnings for its third quarter ended September 29, 2024 ("Third Quarter 2024 ...

Agriculture products company SiteOne Landscape Supply (NYSE:SITE) reported Q3 CY2024 results topping the market’s revenue expectations, with sales up 5.6% year on year to $1.21 billion. Its GAAP ...

SiteOne Landscape Supply, Inc. (NYSE:SITE), a leading distributor of landscape supplies in the United States with a market ...

SiteOne Therapeutics is a biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting Na V 1.7, Na V 1.8, and other voltage-gated ion channels to ...

SiteOne Landscape Supply, Inc. enters 2025 with a clear focus on operational improvements and acquisition-driven growth.

SiteOne Landscape Supply, Inc., together with its subsidiaries, engages in the wholesale distribution of landscape supplies in the United States and Canada. The company provides irrigation ...

Review the current SiteOne Landscape Supply Inc (SITE:XNYS) dividend yield and history to decide if SITE is the best investment for you.

SiteOne Landscape Supply, Inc. remains a leading player in the wholesale distribution of landscape supplies, providing a broad range of products for professional customers in the green industry.

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain. This target has ...

SiteOne quietly emerged with a small amount of funding 10 years ago. Since then, the company has been mostly stealthy. In 2017, Amgen led a $15 million Series B investment in the startup, a deal ...